Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders
Main Article Content
ABSTRACT
Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OII-LPD) is defined by the World Health Organization classification 2016 as lymphoid proliferations or lymphomas that arise in patients treated with immunosuppressive drugs for autoimmune disease or conditions other than in the post-transplant setting. OII-LPD patients have a relatively high incidence of extranodal disease (40–50%). The distinct feature of OII-LPD is spontaneous regression after discontinuation of immunosuppressive drugs. The clinical course of OII-LPD after discontinuation of immunosuppressive drugs can be roughly divided into three categories: regression, transient regression followed by relapse or recurrence, and progression. Regression after discontinuation of immunosuppressive drugs was seen in 70% of OII-LPD patients. About 33% of these patients who experienced transient regression had experienced relapse or recurrence. The remaining 30% of patients were without regression even after discontinuation of immunosuppressive drugs. Higher absolute lymphocyte count in peripheral blood at the time of development of OII-LPD and Epstein-Barr virus-encoded RNA (EBER)-positivity are predictive factors of regression.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.